Screener
Rigel Pharmaceuticals RIGL Single reportable segment — Provision for income taxes
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Commercial related expenses | 7,040 | 5,339 |
| Outside clinical trial related expenses | 6,927 | 4,371 |
| Cost of product sales | 4,606 | 4,409 |
| Consultants and third-party services | 4,006 | 3,409 |
| Other segment items | 3,352 | 3,494 |
| Interest expense, net | 228 | 1,262 |
| Provision for income taxes | 3,003 | 65 |
| Segment income | $8,654 | $11,446 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's single reportable segment — provision for income taxes?
- Rigel Pharmaceuticals (RIGL) reported single reportable segment — provision for income taxes of $3M in Q1 2026.
- What does single reportable segment — provision for income taxes mean?
- Represents the estimated income tax expense or benefit recognized by the segment during the reporting period. This reflects the impact of tax regulations and deferred tax assets or liabilities on the company's bottom line.
Ask your AI about Rigel Pharmaceuticals's single reportable segment — provision for income taxes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude